Rock Springs Capital Management LP Decreases Position in Gossamer Bio, Inc. $GOSS

Posted by George Bondi on Jul 28th, 2026

Rock Springs Capital Management LP cut its stake in shares of Gossamer Bio, Inc. (NASDAQ:GOSS – Free Report) by 87.5% during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,609,492 shares of the company’s stock after selling 11,230,468 shares during the period. Rock Springs Capital Management LP’s holdings in Gossamer Bio were worth $529,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also modified their holdings of the company. Tudor Investment Corp ET AL boosted its holdings in shares of Gossamer Bio by 7.8% in the 3rd quarter. Tudor Investment Corp ET AL now owns 50,103 shares of the company’s stock worth $132,000 after purchasing an additional 3,639 shares during the period. Wealth Enhancement Advisory Services LLC raised its holdings in Gossamer Bio by 24.8% during the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 23,964 shares of the company’s stock valued at $74,000 after buying an additional 4,767 shares during the period. Caitong International Asset Management Co. Ltd raised its holdings in Gossamer Bio by 22.1% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 26,408 shares of the company’s stock valued at $82,000 after buying an additional 4,771 shares during the period. Deutsche Bank AG lifted its position in Gossamer Bio by 0.4% in the fourth quarter. Deutsche Bank AG now owns 1,284,335 shares of the company’s stock worth $3,981,000 after buying an additional 5,414 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV lifted its position in Gossamer Bio by 52.3% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 23,983 shares of the company’s stock worth $74,000 after buying an additional 8,239 shares during the last quarter. 81.23% of the stock is owned by institutional investors.

Gossamer Bio Stock Performance

Shares of GOSS stock opened at $0.20 on Tuesday. The stock has a 50 day moving average price of $0.18 and a 200 day moving average price of $0.80. Gossamer Bio, Inc. has a 52-week low of $0.11 and a 52-week high of $3.87. The firm has a market capitalization of $46.80 million, a P/E ratio of -0.25 and a beta of 2.04.

Gossamer Bio (NASDAQ:GOSS – Get Free Report) last announced its quarterly earnings data on Friday, May 15th. The company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The business had revenue of $16.95 million during the quarter, compared to the consensus estimate of $4.67 million. As a group, sell-side analysts forecast that Gossamer Bio, Inc. will post -0.37 EPS for the current year.

Analyst Ratings Changes

Several research analysts have commented on GOSS shares. Weiss Ratings lowered shares of Gossamer Bio from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Tuesday, May 19th. HC Wainwright reissued a “buy” rating on shares of Gossamer Bio in a research note on Monday. Three investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $3.20.

View Our Latest Report on GOSS

Gossamer Bio Company Profile

(Free Report)

Gossamer Bio, Inc is a clinical-stage biopharmaceutical company headquartered in San Diego, California. Founded in 2012, the company is focused on discovering and developing oral, once-daily therapies for immune-mediated and inflammatory diseases, as well as oncology indications. Gossamer Bio leverages a deep pipeline of small-molecule candidates aimed at improving patient outcomes in areas of high unmet need.

The company’s lead programs include GB004, an S1P1 receptor modulator in late-stage development for ulcerative colitis, and GB1275, a CD11b modulator being investigated in solid tumors and hematologic malignancies.